Introduction &
Diabetic nephropathy is a leading cause of endstage renal disease (ESRD), and accounts for signifi cant morbidity and mortality in Western societies ( Maisonneuve et al., 2000 ) . The aetiology of the progressive structural and functional changes ultimately resulting in overt diabetic nephropathy is not fully elucidated. Recent advances in this area however, have provided clues to the specifi c mechanisms involved in the onset and progression of this disoder. Most likely, renal damage in diabetes is the result of an interaction between hemodynamic and metabolic abnormalities , as evidenced by the major clinical determinants of diabetic nephropathy remaining hyperglycaemia ( 
Abstract &
Diabetic nephropathy (DN), the most common cause of end stage renal disease in developed nations, is thought to result from interactions between metabolic and haemodynamic factors. Specifi c metabolically driven, glucose dependent pathways are activated within diabetic renal tissues. These pathways induce oxidative stress, polyol pathway fl ux, hexosamine fl ux and accumulation of advanced glycated end-products (AGEs). Haemodynamic factors are also implicated in the pathogenesis of DN and include elevations of systemic and intraglomerular pressure and activation of various vasoactive hormone pathways including the renin-angiotensin aldosterone system (RAAS), endothelin and urotensin. These altered hemodynamics act independently and in concert with metabolic pathways, to activate intracellular second messengers such as protein kinase C (PKC) and MAP kinase (MAPK), nuclear
The vasoactive hormone angiotensin II (AII), plays a critical role not only in the regulation of systemic and glomerular hemodynamics, but also in glomerular hypertrophy and sclerosis. Indeed, therapeutic blockade of the renin-angiotensin system with angiotensin converting enzyme (ACE) inhibitors and angiotensin II type 1 receptor (AT1R) antagonists suppresses the development and progression of diabetic nephropathy in both type 1 and type 2 diabetic patients ( Brenner et al., 2001 , Lewis et al., 1993b , Mogensen et al., 2000b . During recent years, a myriad of data have emerged on the diverse effects associated with angiotensin II including growth stimulation, induction of fi brogenesis and immuno-modulation, which are clearly transcription factors such as nuclear factor-B (NF-B) and various growth factors such as the prosclerotic cytokines, transforming growth factor-1 (TGF-1), connective tissue growth factor (CTGF) and the angiogenic, permeability enhancing growth factor, vascular endothelial growth factor, VEGF. Ultimately these molecular mechanisms lead to increased renal albumin permeability, and extracellular matrix accumulation, which results in increasing proteinuria, glomerulosclerosis and tubulointerstitial fi brosis. In the past, the treatment of diabetic nephropathy has focused on control of hyperglycemia and the interruption of the RAAS with certain antihypertensive agents. Newer novel targets, some of which are linked to glucose dependent pathways, appear to be a major focus of new therapies directed against the development and progression of renal damage as a result of diabetes. It is likely that resolution of diabetic nephropathy will require synergistic therapies to target multiple mediators of this disease.
beyond the classical vasopressor function described for this vasoactive peptide ( Wolf, 1998 ) . Other vasoactive proteins such as endothelin (ET), nitric oxide (NO) and urotensin II (UII) have also recently gained attention in diabetic nephropathy. Suppression of the actions of endothelin with endothelin A receptor antagonists ( Nakamura et al., 1995a ) have shown benefi cial outcomes in experimental models of diabetic nephropathy. The metabolic abnormalities seen in the diabetic kidney are diverse. It is obvious from studies in diabetic patients, that strict glycaemic control is an important strategy to retard the progression of nephropathy (1998, Diabetes Control and Complications Trial Research Group, 1993 ), although clinically this not always attainable. There are four main pathways that have been implicated to explain how hyperglycaemia per se leads to the development of diabetic complications, including nephropathy. These include increased fl ux via either the polyol and hexosamine pathways, accumulation of advanced glycation end products and activation of protein kinase C ( Brownlee, 2001 , Sheetz and King, 2002 ) which are each discussed in detail later in this review. While manipulation of each of these individual pathways has shown benefi t in experimental models, their role in the clinical treatment of diabetic nephropathy remains to be determined. Furthermore, several in vitro and in vivo studies have implicated transforming growth factor-(TGF-), a fi brogenic cytokine, as a key effector molecule in promoting diabetic renal disease ( Anderson et al., 1989 , Cooper et al., 1988 , Zatz et al., 1985 . Moreover, other growth factors have been implicated in progression of diabetic nephropathy such as vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), and connective tissue growth factor (CTGF) in conjunction with intracellular signalling molecules such as mitogen-activated protein kinase (MAPK), nuclear factor kappa B (NF-B) and protein kinase C (PKC) ( Flyvbjerg et al., 2002 ) .
Haemodynamic factors & Renin-angiotensin system (RAS)
Initial studies emphasised the role of haemodynamic factors in DN, in particular the potential role of inhibitors of the RAS as renoprotective agents in experimental diabetes ( Anderson et al., 1989 , Zatz et al., 1986 . Micropuncture studies in diabetic rats revealed a range of intrarenal haemodynamic abnormalities including increased intraglomerular pressure, increased single nephron glomerular fi ltration rate (GFR) and preferential afferent versus efferent arteriolar vasodilatation ( Zatz et al., 1986 ). This increase in intraglomerular pressure was considered to play a pivotal role in mediating progressive glomerular injury in a range of progressive renal diseases including diabetes ( Hostetter et al., 1982 ) . This hypothesis was based on studies where intraglomerular pressure was reduced by a range of treatments including ACE inhibitors ( Zatz et al., 1986 ) and low protein diets ( Zatz et al., 1985 ) in association with reduced renal injury. This central role for intraglomerular hypertension extended our understanding of the importance of haemodynamic factors in mediating renal injury in diabetes. It emphasised that determinants of progression of DN included not only systemic hypertension but also specifi c intrarenal haemodynamic changes, which were occurring even in the setting of a normal blood pressure ( Zatz et al., 1986 ( Burns, 2000a ) . In general, plasma measurements of various components of the RAS are low or normal in diabetes ( Leehey et al., 2000 ) . However, it is well appreciated that the RAS also acts at a local level within the kidney. Measurements of the various renal components of the RAS by a range of techniques have been contradictory with reports of reduced, normal or decreased levels of renin and AII in the diabetic kidney ( Anderson et al., 1993 , Campbell et al., 1999 , Kalinyak et al., 1993 ) . In vitro studies in proximal tubular cells have described increased angiotensinogen expression in response to glucose ( Zhang et al., 1999 ) . In mesangial cells, glucose per se has also been reported to stimulate angiotensin II production in association with increased TGF-1 production ( Singh et al., 1999 ) . It is possible that rather than a change in the levels of these renal components, that diabetes may alter their distribution within the various kidney compartments. In experimental diabetes, Anderson et al have reported a redistribution of ACE to vascular and glomerular sites in diabetes ( Anderson et al., 1993 ). We have documented a similar phenomenon in diabetic (mRen-2)27 transgenic rat, a model which involves the introduction of the murine renin gene into the rat genome ( Mullins et al., 1990 ). This results in increased expression of various components of the RAS, particularly outside the kidney with subsequent development by these arts of an elevation in blood pressure. These diabetic rats have increased proximal tubular renin expression particularly in damaged tubules which is reduced at this site by an AT1 receptor antagonist, in the context of an increase in renin expression at the major site of synthesis, the juxtaglomerular apparatus . This increase in proximal tubular renin is associated with a local increase in expression of AII. Further evidence for the local activation of the RAS in the tubular compartment has been suggested in studies demonstrating an early increase in proximal tubular renin in experimental diabetes ( Zimpelmann et al., 2000 ) . The authors postulated that this could contribute to a local increase in AII resulting ultimately in tubulointerstitial fi brosis in this model. These fi ndings empha-sise changes in the distribution of the RAS in the diabetic kidney, which may be important in mediating progressive renal injury. Another important explanation for the disparity in the various measurements of both the systemic and intrarenal RAS in diabetes and the responsiveness of the diabetic kidney to blockade of the RAS may relate to increased sensitivity of the diabetic kidney to AII as has been suggested by several investigators ( Burns, 2000b , Kennefi ck et al., 1996 . In addition, recent long term clinical follow up of patients with diabetic nephropathy who are treated with ACEi has revealed the principle of " aldosterone escape " . ACE inhibitors do not effectively suppress levels of the mineralocorticoid, aldosterone in the long term, and lead to suboptimal renoprotection as a result of ongoing prosclerotic effects. Indeed, these agents and others in this antihypertensive class may actually increase aldosterone levels, and thus may potentiate aldosterone ' s negative effects on the heart, blood vessels, and kidneys. One study of 45 patients with early type 2 diabetic nephropathy, treated with an ACE inhibitor for 40 weeks, showed that 40 % of patients developed evidence of aldosterone escape and no longer showed maximal antiproteinuric effects of ACE inhibition ( Sato and Saruta, 2003 ) . Although AII has haemodynamic effects both at the systemic level and intra-renally, it is becoming increasingly evident that AII has a range of non-haemodynamic effects relevant to progressive renal injury ( Wolf and Ziyadeh, 1997 ) . It has been difficult to separate the haemodynamic from nonhaemodynamic effects in vivo but the use of cultured cells has allowed investigators to explore these additional effects of AII. AII induces extracellular matrix accumulation, a hallmark of DN primarily via stimulation of the prosclerotic cytokine, TGF-1 ( Kagami et al., 1994 ) . AII may also infl uence a range of other cytokines and in particular it may activate a range of intracellular mediators implicated in progressive renal injury such as PKC ( Arendshorst et al., 1999 , Nagahama et al., 2000 ) and the nuclear transcription factor, NF-B ( Ruiz-Ortega et al., 2000 ). Finally, AII may also infl uence pathways considered to be primarily metabolic, such as advanced glycations. Recent studies from our group in models of AII infusion, have demonstrated that AII can specifi cally manipulate the expression of AGE receptors and their renal and serum accumulation . Conversely, the infusion of AGEs into normal rodents produces changes in the reninangiotensin system reminiscent of those seen in our models of DN . AII also infl uences cell growth, proliferation and apoptosis via a range of pathways not yet fully defi ned ( Bonnet et al., 2001 , Shankland and Wolf, 2000 ) . In particular, cell cycle regulation by may be linked to various changes in the diabetic kidney including renal hypertrophy ( Shankland and Wolf, 2000 ) . Indeed, the reduction in glomerular hypertrophy often observed with blockade of the RAS ( Allen et al., 1997 ), supports a role for AII in cell cycle regulation. Studies in STZ diabetic rats treated with ACE inhibitors demonstrated reduced glomerular volume in addition to abolition of glomerular expression of the cyclin-dependent kinase inhibitors p 16INK4 and p 27Kip1 ( Wolf, 2000 ) . 
Other vasoconstrictors
Other vasoactive hormones have been postulated to play a role in mediating progressive renal injury ( Johnston et al., 1998b 
Vasodilators
The formation and degradation of many vasoactive hormones rely on zinc dependent metallopeptidases, the most well known example being ACE. Other enzymes include fi rstly neutral endopeptidase (NEP), which plays an important role in the degradation of natriuretic peptides as well as bradykinin and secondly, endothelin converting enzyme (ECE), which is involved in generation of biologically active endothelin ( Johnston et al., 1998a ) . A major target has been inhibition of both ACE and NEP leading to a lack of degradation of vasodilatory hormones and reduced formation of AII. This approach would theoretically lead to increased vasodilation resulting in greater hypotensive efficacy and potentially superior renoprotection. Such agents have now been explored in both preclinical and clinical contexts. In the subtotal nephrectomy model, several groups have reported renoprotective effects of the dual ACE / NEP inhibitor, omapatrilat ( Cao et al., 2001b ). In the diabetic SHR, our group has shown with another ACE / NEP inhibitor antihypertensive effi cacy in association with benefi cial effects on urinary albumin excretion ( Davis et al., 2003b , Tikkanen et al., 1998 ). However, the high prevalence of angioedema with ACE / NEP inhibition using omapatrilat, particularly in African American subjects and the presence of persistent cough, attributable to its potent ACE inhibition have delayed and potentially halted further clinical development of this compound. Nevertheless, other ACE / NEP continue to be developed by some pharmaceutical companies. Nitric oxide (NO) is a widely expressed signalling molecule, which plays a major role in most cellular and tissue functions throughout the body. NO is formed via conversion of L-arginine to L-citrulline, catalysed by nitric oxide synthase (NOS). There are three structurally distinct NOS isoforms, neuronal (nNOS), inducible (iNOS) and endothelial (eNOS) ( Komers et al., 1994 ) and their structure and function have been previously reviewed extensively ( Hocher et al., 2001 ). The status of the nitric oxide pathway in diabetes appears to be both organ and duration specifi c with evidence of nitric oxide defi ciency in the macrovascular tree particularly with increasing duration of diabetes ( Pieper, 1999 ) . By contrast, it has been considered that in the diabetic kidney there may be increased nitric oxide levels and / or action ( Komers et al., 1994 , Tolins et al., 1993 . Initial studies in the kidney suggested increased nitric oxide levels in the diabetic kidney, based on the relatively crude marker of urinary nitrate / nitrite production ( Komers et al., 1994 ) . Specifi c renal vascular studies have demonstrated impaired acetylcholine induced endothelial dependent relaxation. In that study NO dependent vasodilation was enhanced whereas vasodilation mediated by endothelium derived hyperpolarizing factor was severely impaired ( De Vriese et al., 2000 ) .
Further studies suggesting increased NO in the diabetic kidney were based on experiments using non-selective inhibitors of NO synthase (NOS) which showed reductions in GFR and renal plasma fl ow in hyperfi ltering, diabetic rats ( Komers et al., 1994 . This contrasts with initial studies suggesting a possible role for iNOS in diabetic nephropathy and in particular diabetic hyperfi ltration. Indeed, administration of a selective iNOS inhibitor, L-imino-ethyl-lysine failed to infl uence renal function in experimental diabetic rats ( Veelken et al., 2000 ) . It remains to be determined if these effects of NO on early renal haemodynamic abnormalities are of any long-term relevance, particularly to the development of renal impairment and ultrastructural injury in diabetes. Our own studies using the non-specifi c inhibitor of NO synthase, L-NAME, did not clearly show renoprotection ( Soulis et al., 1997a ) .
Metabolic Pathways & Advanced glycation
AGEs are generated as a result of a series of sequential biochemical reactions, some of which are poorly defi ned, resulting in the non-enzymatic glycation of free amino groups on protein, lipoproteins and nucleic acids by reducing sugars ( Brownlee, 1994 ). This process is accelerated in the presence of oxygen with some AGEs can considered be ' glycoxidation ' products ( Fu et al., 1994 , 1999 ) . Some studies have used exogenous intravenous administration of AGEs to mimic diabetic serum concentrations, which has been reported to induce complications ( Vlassara et al., 1994 ) . In fact, AGEs from dietary sources, of which between 50 -80 % are absorbed across the gut, are now considered important contributors to the circulating pool of AGEs in diabetes, as they are present at high concentrations in western style diets ( Forster et al., 2005 ) . Indeed, there are clear benefi ts of specifi c reduction of dietary AGE intake in both experimental DN ( Uribarri et al., 2003 ) and in patients with DN ( Koschinsky et al., 1997 ) . This suggests that an important contribution to AGE induced damage may be via the interaction of circulating AGEs with receptors or binding proteins. In early studies by Nicholls and Mandel in diabetic mice, renal AGE accumulation was detected which could be attenuated by either pancreatic islet transplantation or treatment with an inhibitor of AGE formation, aminoguanidine ( Nicholls and Mandel, 1989 ). Subsequently, our group evaluated the role of aminoguanidine in diabetic rats and showed that reduced renal AGE accumulation with this drug was associated with retardation in the development of albuminuria and attenuation of mesangial expansion ( Soulis-Liparota et al., 1991 ). Since advanced glycation end products accumulate over time, we explored the role of early versus delayed introduction with aminoguanidine and its effects on renal injury in diabetes ( Soulis et al., 1996 ) . In a 32 week study, diabetic rats were randomised to receive aminoguanidine over the fi rst or last 16 weeks of the study period. It was demonstrated that both treatments had similar effects on renal AGE accumulation, albuminuria and mesangial expression consistent with the hypothesis that the renal injury in diabetes is linked to the time of exposure to increased AGEs. ). This is associated with an increase in RAGE but a decrease in AGE-R1 expression.
Other effects of AGEs appear to be the stimulation of various cytokines including TGF presumably via receptor dependent pathways including RAGE. Increased expression of renal TGF-1 as well as PDGF and the extracellular matrix protein, type IV collagen in the diabetic kidney can be attenuated by aminoguanidine, particularly in the tubulointersitium ( Kelly et al., 2001b ) . A similar effect has been reported in a model of type 2 diabetes, the OLETF rat, by a Japanese group which described reduced TGF-1 and VEGF expression after 68 weeks of treatment with a novel AGE inhibitor, OPB-9195 ( Tsuchida et al., 1999 ) .
Aldose Reductase / Polyol Pathway
The accumulation of polyols within the kidney has been postulated to play a role in the development of DN ( ᭹ ᭤ Fig. 1 ). Although this pathway has been most extensively investigated in terms of neuropathy, more limited exploration of this pathway has been performed in renal disease ( Dunlop, 2000 ) . Within the polyol pathway, glucose is reduced to sorbitol by aldose reductase (AR),
an NADPH dependent aldo-keto reductase. Sorbitol accumulation is associated with depletion of myoinositol and changes in the cellular redox potential ( Greene et al., 1987 ) . The importance of polyols in activating pathways relevant to DN has been emphasised with the demonstration that aldose reductase inhibition is associated with reduced PKC activation and TGF-1 production in human mesangial cells in response to glucose ( Ishii et al., 1998 
Hexosamine pathway
It has been hypothesised that the hexosamine pathway, is involved in the development of diabetic complications ( James et al., 2000 , Nerlich et al., 1998 , Schleicher and Weigert, 2000 ) . In this pathway, glucose is converted to glucose-6-phosphate via hexokinase and subsequently to fructose-6-phosphate as part of the glycolytic pathway ( ᭹ ᭤ Fig. 1 ). Fructose -6-phosphate is subsequently diverted from glycolysis to provide a substrate for the formation of proteoglycans and O-linked glycoproteins ( Brownlee, 2001 ). This occurs under the control of the rate limiting enzyme glutamine:fructose -6-phosphate amidotransferase (GFAT), using glutamine as an amino donor. A series of additional reactions then occur ultimately leading to the generation of other glucosamines, which serve as precursors for amino sugars used for the synthesis of proteoglycans, glycolipids and glycoproteins. To explore this pathway investigators have overexpressed the enzyme GFAT ( James et al., 2000 ) or directly inhibited this enzyme. It appears that increased fl ux through the hexosamine pathway is associated with PKC activation and increased TGF-1 expression ( Weigert et al., 2001 ). Indeed, glucose induced TGF-1 expression and subsequent matrix production can be inhibited by GFAT blockade using either azaserine or an antisense oligonucleotide approach ( Schleicher and Weigert, 2000 ) . Increased fl ux through the hexosamine pathway in DN may also be facilitated by glucose transporters such as GLUT-1 ( Heilig et al., 1995 ) . Initial studies showed that the effects of glucose on collagen production could be reproduced in mesangial cells overexpressing GLUT-1 despite exposure to normal glucose levels ( Heilig et al., 1995 ) . Subsequently it was demonstrated that glucose induces GLUT-1 expression and translocation in mesangial cells ( Heilig et 
Oxidative Stress and Reactive Oxygen Species
Oxidative stress leading to the formation of reactive oxygen species (ROS) is recognised as a key component in the development of diabetic complications ( ᭹ ᭤ Fig. 1 ) The elevated oxidative stress seen in diabetes is the result of an imbalance between ROS generation and endogenous anti-oxidant activity, including free radical scavengers and enzyme systems. Indeed, type 1 diabetic patients with nephropathy have abnormal antioxidant profi les ( Hodgkinson et al., 2003 ) . Antibodies to AGE-R2 and RAGE are also able to inhibit AGE-dependent depletion of cellular anti-oxidant systems such as glutathione peroxidase ( Lander et al., 1997 ) . Glycation of anti-oxidants such as Cu-Zn-superoxide dismutase (SOD-1) also contribute to the decline in anti-oxidant activity ( Fujii et al., 1996 ) which may be related to specifi c SOD-1 gene mutations ( Kato et al., 2000 ) . While oxidative stress can augment the formation of AGEs through glycoxidation , AGEs can also lead to enhanced formation of free radicals, both directly through catalytic sites in their molecular structure ( Yagihashi, 1997 ) and via stimulation of membrane-bound NAD(P)H oxidase through the RAGE receptor ( Wautier et al., 2001 ) . In rodent models, oxidative stress, induced following the hepatic infusion of diabetic erythrocytes can be prevented by pre-treatment with anti-RAGE IgG ( Wautier et al., 2001 ) . Animal studies have shown that potent anti-oxidants may protect against the development of diabetic nephropathy ( Jang . However, human studies with less potent antioxidants such as -tocopherol ( Yagihashi, 1997 ) have been, in general, disappointing and this has been attributed partly to lack of penetration of these agents to target areas and the lack of specifi city. Our own studies have demonstrated that oxidative stress is increased in diabetic animals in proportion to AGE accumulation . There is also evidence in human diabetic glomerular lesions of increased oxidative stress and AGE accumulation ( Suzuki et al., 1999 ) , both of which may be attenuated by good glycaemic control ( Odetti et al., 1996 ) . Boldine, a mitochondrial free radical scavenger, has proven benefi cial in experimental diabetes in combating mitochondrial free radical production and lipid peroxidation in the kidney ( Jang et al., 2000 ) . The utility of boldine and related agents as renoprotective agents may ultimately be related to their ability to combat oxidative stress, however this remains to be directly tested. It remains to be determined if oxidative stress in purely an early event in hyperglycaemia induced vascular injury leading to the activation of other pathways or if oxidative stress is also implicated in downstream critical events for mediating vascular and in particular renal damage. To further explore this issue will require better markers of oxidative stress as well as the use of more specifi c inhibitors of this pathway.
Intracellular second messengers & Protein kinase C (PKC)
Evidence has accumulated over the last decade implicating PKC as an important mediator of diabetes induced vascular dysfunction ( Inoguchi et al., 1992 , Xia et al., 1994 . Initial studies using various cell types including mesangial cells indicated that effects of hyperglycemia on mesangial dysfunction could be mimicked by phorbol esters, direct activators of PKC and could be attenuated by non-specifi c PKC inhibitors ( Studer et al., 1993 ) . Further studies identifi ed that certain isoforms of this intracellular second messenger were preferentially activated in the diabetic kidney ( Koya et al., 1997 ) and therefore these isoforms were considered as targets for development of inhibitors. A specifi c PKC inhibitor, LY333531 (ruboxistaurin), was developed and in streptozotocin diabetic rats over 12 weeks this agent was shown to attenuate glomerular hyperfi ltration, reduce albuminuria and decrease expression of TGF ß and various extracellular matrix proteins ( Ishii et al., 1996 , Koya et al., 1997 . More recently, this PKC inhibitor was administered to db / db ( + / + ) mice, a model of type 2 diabetes for 16 weeks and in the STZ diabetic (mRen-2)27 rat ( Kelly et al., 2003 ) . In addition to normalising glomerular PKC activity in these models, urinary albumin excretion was reduced as was TGF-1, fi bronectin and type IV collagen expression. A number of clinical trials for various diabetic complications are in progress or just completed with ruboxistaurin. The results of one of these trials have been recently published evaluating the effect of this agent on albuminuria in type 2 diabetic patients although it was not significantly powered to show a defi nitive benefi t between treated and untreated patient groups ( Tuttle et al., 2005 
Nuclear factor kappa B (NF-B)
NF-B is a transcription factor composed of two subunits, the most common of which are the p50 and p65 subunits ( Barnes and Larin, 1997 ). NF-B is ubiquitously expressed and is stored in an inactive form bound to inhibitors in the cytoplasm. P50 is usually complexed with the p65 subunit and therefore has the ability to transactivate numerous genes including cytokines, adhesion molecules, NO synthase, angiotensinogen and many other infl ammatory and proliferative proteins implicated in the process of diabetic nephropathy ( Barnes and Larin, 1997 ). NF-B is activated by a range of stimuli including glucose ( Pieper and Riazulhaq, 1997 ) and ROS ( Nishikawa et al., 2000 ) . This phenomenon appears to be PKC dependent ( Pieper and Riazulhaq, 1997 ) and is able to be prevented by antioxidants ( Nishikawa et al., 2000 ) . AGEs are also involved in activation of NF-B via a RAGE-dependent pathway leading to its translocation to the nucleus where it induces transcription ( Yan et al., 1994 ) . The promoter region of the RAGE gene also contains NF-B binding sites ( Li and Schmidt, 1997 ). This provides a pathway for perpetuation of injury since NF-B is not only activated in response to RAGE, but RAGE is also activated by NF-B. This is supported by studies in which mutations of both NF-B like binding sites in the promoter region of RAGE led to stimulated promoter expression ( Li and Schmidt, 1997 ). The NF-B inhibitor, pyrollidine dithiocarbamate (PDTC) has been studied in non-diabetic models of fi brosis and shown to confer renoprotection ( Muller et 
MAP kinase
Mitogen-activated protein kinases (MAPK) are a major signalling system which translates extracellular signals to intracellular responses ( Seger and Krebs, 1995 ) . Three major subgroups have been identifi ed, the ERK family, C-jun N-terminal kinase (JNK) / stress-activated protein kinase (SAPK) and p38 MAPK. The MAPK cascades play a central role in a range of biological processes relevant to DN including cell growth, differentiation and apoptosis ( Choi, 2000 ). Glucose has been reported to activate MAPK, and in particular p38 MAPK ( Igarashi et al., 1999 ) . This increase in MAPK has also been noted in glomeruli from diabetic rats . The exact role of this family of kinases is not clear but they appear to have relevance to diabetic nephropathy. Already these agents have been demonstrated to have a role in non-diabetic renal disease, and thus fi ndings from studies using MAPK inhibitors in experimental diabetes are keenly awaited.
Cytokines

& Transforming Growth Factor (TGF-)
Transforming growth factor beta is a superfamily with three mammalian isoforms. The major isoform, TGF-1 is synthesised as an inactive or latent form, which subsequently is subjected to proteolytic cleavage leading to the generation of the active form. TGF-1 binds to the type II receptor and subsequently binds to the type I receptor ( Wrana et al., 1994 ) inducing phosphorylation and intracellular signalling involving the Smad proteins ( Massague, 1998 ) . As previously reviewed, these actions of TGFvia the Smad pathway, are modulated by a range of signalling pathways including NF-B and MAPK ( Schiffer et al., 2000 ) . TGF-1 is considered the pivotal cytokine in mediating collagen deposition in the kidney ( Border and Noble, 1994 , Isaka et al., 1993 ) . Not only does it stimulate gene expression of various matrix proteins but it infl uences the matrix degrading enzyme pathways by inhibiting the synthesis of matrix metalloproteinases and stimulating the production of metalloproteinase inhibitors (TIMPs) ( Border and Noble, 1994 ). In vitro studies have shown that a range of stimuli increase TGF-expression ( Table 1 ) and STZ diabetic rats ( Sharma et al., 1996 ) . Although most of the benefi ts have been attributed to TGF-1, Hill et al . have suggested that another isoform, TGF-2, is closely linked to fi brogenesis in diabetic nephropathy ( Hill et al., 2000 ) . Consistent with this view, systemic delivery of CAT-152, a neutralizing anti-TGF-2 antibody, during the acute stage of diabetic nephropathy reduced the rate of pathogenic fi brosis including attenuation of collagen type I synthesis and reduction in albuminuria in STZ-induced diabetic rats ( Hill et al., 2000 ) . Novel triarylimidazole and 2,4,5-pyridinylimidazole TGF-receptor antagonists, have been developed by GlaxoSmithKline for the treatment of different fi brotic diseases including diabetic nephropathy ( Sharma et al., 1996 ) . These agents specifi cally inhibit the phosphorylation of smad2 or smad3 via blockade of activin-like kinase 5, the type I receptor for TGF-. These agents may be useful in diabetic nephropathy although are not fully characterized as renoprotective agents in diabetes. However, TGF-expression is decreased by the treatments such ACEi ( Davis et al., 2003a ), AT1R antagonists ( Koga et al., 2002 ) , antiglycation inhibitors ( Forbes et al., 2003 , Kelly et al., 2001a , Kim et al., 2000b and statins in experimental diabetes. Therefore, TGF-1 may not need to be specifi cally targeted to reduce it levels or action and no currently available therapies exist to directly target it in clinical DN.
Connective tissue growth factor
Another prosclerotic cytokine, connective tissue growth factor (CTGF) has been demonstrated to have increased renal and in particular, glomerular expression in diabetes ( Murphy et al., 1999 , Riser et al., 2000a . The synthesis of this peptide is thought to be stimulated by TGF-1, hyperglycemia or cyclic mechanical stretch ( Riser et al., 2000a ) , these stimuli all being relevant to the pathogenesis of DN. Furthermore, CTGF could induce its own expression providing a potential mechanism for inducing a perpetual cycle of progressive renal injury. Recently, it has also been reported that CTGF may potentiate some of the actions of TGF-, by facilitating the binding of TGF-to its type II receptor ( Abreu et al., 2002 ) . CTGF has been reported to be elevated in two different rodent models of DN ( Riser et al., 2000b , Twigg et al., 2002 . In addition, CTGF is also increased in both early and late diabetic nephropathy in humans ( Ito et al., 1998 ) . Interestingly, AGEs have been reported to increase CTGF expression, initially in ( Twigg et al., 2001a ) but subsequently in mesangial cells ( Twigg et al., 2001b ) . Indeed within our own study in STZ induced DN, the AGE inhibitor aminoguanidine ameliorated increases in CTGF ( Twigg et al., 2002 
Vascular endothelial growth factor (VEGF)
Vascular endothelial growth factor (VEGF) is a cytokine whose major role in diabetes has been considered to be in the pathogenesis of diabetic retinopathy and in particular retinal neovascularisation ( Aiello et al., 1994 ). However, it should be appreciated that vascular endothelial growth factor is highly expressed in the kidney, primarily in the glomerular podocytes but also in distal tubules and collecting ducts ( Cooper et al., 1999 ). Its major receptor, VEGF-R2 is also expressed in the kidney, primarily on endothelial cells but also on cortical interstitial fi broblasts. A range of stimuli for VEGF expression and / or signaling, have been identifi ed which may be relevant to DN. These include hyperglycemia, AGEs, PKC, mechanical stretch and AII ( Gruden et A range of other cytokines have also been implicated in DN. These include the IGFs and EGF, their role having been reviewed in detail previously ( Flyvbjerg, 2000 ) .
Conclusion &
Many of experimental studies described above have given us novel insights into the mechanisms responsible for diabetic nephropathy. Indeed, many of the agents utilised in these studies are currently being developed in various clinical trial programs. The knowledge we have today on the pathogenesis of diabetic nephropathy indicates that diabetes associated initiation and perturbation of various metabolic and hemodynamic pathways activate growth factors, cytokines and intracellular second messengers. Blockade of the RAS has been investigated extensively and is now considered fi rst line treatment for diabetic nephropathy by many international organizations (BabaeiJadidi et al.). Newer treatments such as inhibition of the AGE pathway at the level of formation, degradation or receptor binding may be also be particularly useful in both the early and late stages of diabetic nephropathy. It is predicted that combination therapy with inhibitors of the RAS and the advanced glycation pathway may be superior to either therapy alone ( Davis et al., 2003a ) . Finally, it is likely that recent insights into the pathogenesis of diabetic nephropathy will lead to a variety of new treatments with additional benefi ts not only in slowing but also possibly reversing the progression of renal dysfunction that occurs in this disorder. 
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